FDA
-
-
-
-
-
-
-
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
-
-
-
-
-
-
-
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
-
-
-
-
-
-
-
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
-
-
-
-
-
-
-
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
-
-
-
-
-
-
-
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
-
-
-
-
-
-
-
Alvotech (ALVO) and Teva (TEVA) Announce U.S. FDA Approval of Additional Presentation of SELARSDI, Expanding its Label
-
-
-
-
-
-
-
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
-
326,830 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

